Volume: 8 Issue: 2
Year: 2020, Page: 52-56, Doi: https://doi.org/10.47799/pimr.0802.12
Objective: To study the role of Indomethacin in patients with Idiopathic Polyhydramnios who were symptomatic.
Methods: A prospective study was conducted in Prathima Institute of Medical Sciences, Karimnagar from September 2017 to May 2019. Eighteen patients with Idiopathic Polyhydramnios who presented with respiratory embarrassment, premature opening of os or presence of uterine activity were given Indomethacin orally at a dose of 25mg 6th hourly. The significance of changes in AFI was tested by paired t test.
Results: There was significant improvement in the symptoms in all the eighteen patients. The mean age of the patients in our study was 26.4±5.5 years. The majority 14(77.7%) of women were multigravida. Mean gestational age at presentation was 30.78±1.56 weeks. Mean AFI at presentation was 31.56±3.68 cm. Indomethacin was given orally at a dose of 25mg, every 6th hourly for a mean duration of 22.5±6.38 days. Mean AFI at the end of treatment was 20.28±5.64 cm. Pregnancy was prolonged by an average of 5.5±1.89 weeks. The difference in AFI at the end of treatment was statistically significant (p<0.05). Oligohydramnios was seen in one patient. Mean gestational age at delivery was 36.28±1.41 weeks. 17(94.4%) of them had good neonatal outcome. There was one neonatal death at< 7 days of birth.
Conclusion: Indomethacin significantly decreases amniotic fluid volume in patients with Idiopathic Polyhydramnios and relieves symptoms but close surveillance is necessary.
Keywords: Isolated Polyhydramnios , Indomethacin, AFI
1. Brace RA. Physiology of amniotic fluid volume regulation. Clin Obstet Gynecol. 1997 ;40(2):280-289.
2. Underwood MA, Gilbert WM, Sherman MP. Amniotic fluid: not just fetal urine anymore. J Perinatol. 2005;25(5):341-348.
3. Kollmann M, Voetsch J, Koidl C, et al. Etiology and perinatal outcome of polyhydramnios. Ultraschall Med. 2014;35(4):350-356.
4. Pri-Paz S, Khalek N, Fuchs KM, et al. Maximal amniotic fluid index as a prognostic factor in pregnancies complicated by polyhydramnios.Ultrasound Obstet Gynecol. 2012;39(6):648-653.
5. Leung WC, Jouannic JM, Hyett J, et al. Procedure-related complications of rapid amniodrainage in the treatment of polyhydramnios.Ultrasound Obstet Gynecol. 2004 ;23(2):154-158.
6. Cabrol D, Landesman R, Muller J, et al. Treatment of polyhydramnios with prostaglandin synthetase inhibitors (Indomethacin). Am J Obstet Gynecol. 1987;157(2):422- 426.
7. Neibyl JR, Blake DA, WhiteRD, et al. The inhibition of premature labour with indomethacin. Am J Obstet Gynecol. 1980;136(8):1014-1019.
8. Bhat R, Vidyasagar D, Vadapally M, et al. Disposition of indomethacin in preterm infants. J Pediatr. 1979;95(2):313-316.
9. Souter D, Harding J, McCowan L, et al. Antenatal indomethacin-adverse fetal effects confirmed. Aust N Z J Obstet Gynecol. 1998;38(1):11-16.
10. Lapaire O, Holzgreve W, Zanetti- Daellenbach R, et al. Polyhydramnios: an Update. Donald Sch J Ultrasound Obstet Gynecol. 2007;1(1):73-79.
11 Shrestha A, Chawla CD. Role of indomethacin in polyhydramnios. Sri Lanka J Obstet and Gynecol. 2013;35(2):50-52.
12. Sandlin AT, Chauhan SP, Magann EF. Clinical relevance of sonographically estimated amniotic fluid volume: polyhydramnios. J Ultrasound Med 2013; 32 (5) 851-863.
13. Wiegand SL, Beamon CJ, Chescheir NC, et al. Idiopathic Polyhydramnios: Severity and Perinatal Morbidity. Am J Perinatol. 2016;33(7):658-664.
14. Tariq S, Cheema S, Ahmad A, et al .Polyhydramnios: Study of causes and fetal outcome. Professional Med J. 2010;17(4):660-664.
15. LallarMeenakshi, Anamul Haq,Nandal Rajesh. Perinatal outcome in Idiopathic Polyhydramnios. J Obstet Gynaecol. 2015;65(5):310-314.
16. Abhyankar S, Salvi VS. Indomethacin therapy in hydramnios. J Postgrad Med. 2000;46(3):176-178.
17. Carmona F, Martínez-Román S, Mortera C, et al. Efficacy and safety of indomethacin therapy for polyhydramnios.Eur J Obstet Gynecol Reprod Biol. 1993;52(3):175-180.
18. Abou-Ghannam G,Usta IM, Nassar AH. Indomethacin in pregnancy: applications and safety. Am J Perinatol. 2012;29(3):175-186.
19. Block-Abraham Dana,Turan Mina,Crimmins Sarah, et al. Effects of long term Indomethacin exposure on amniotic fluid volume. Am J Obstet Gynecol. 2015;212(1):S234.
20. Kirshon B, Mari G, Moise KJ Jr. Indomethacin therapy in the treatment of symptomatic polyhydramnios.Obstet Gynecol. 1990;75(2):202-205.
21. Mamopoulos M, Assimakopoulos E, Reece EA, et al. Maternal indomethacin therapy in the treatment of polyhydramnios.Am J Obstet Gynecol. 1990;162(5):1225- 1229.
22. Vermillion ST, Scardo JA, Lashus AG, et al. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age.Am J Obstet Gynecol. 1997;177(2):256-261.
Singham G, Achanta V, Siripurapu S, Samantaray SR. The Role of Indomethacin in Isolated Polyhydramnios. Perspectives in Medical Research 2020; 8 (2):52-56. DOI : 10.47799/pimr.0802.12